5 US and Asian Health Care Companies With Good Financial Strength
5 US and Asian Health Care Companies With Good Financial Strength
In light of the coronavirus outbreak in China, five U.S. and Asian health care companies with goodfinancial strengthandprofitabilityare Edwards Lifesciences Corp. (NYSE:EW), Novo Nordisk A/S (NYSE:NVO), Guangdong Zhongsheng Pharmaceutical Co. Ltd. (SZSE:002317), DongKook Pharmaceutical Co. Ltd. (XKRX:086450) and Bumrungrad Hospital PCL (BKK:BH) according to theAll-in-One Screener, a major GuruFocus Premium feature.
鑑於冠狀病毒在中國的爆發，五家財務實力和盈利能力較好的美國和亞洲醫療保健公司愛德華茲生命科學公司。(紐約證券交易所股票代碼：EW)，Novo Nordisk A/S(紐約證券交易所股票代碼：NVO)，廣東中生藥業股份有限公司(深圳證券交易所股票代碼：SZSE：002317)、東國藥業股份有限公司(XKRX：086450)和Bumrungrad醫院PCL(BKK：BH)，根據GuruFocus的主要高級功能All-in-One Screener。
Warning! GuruFocus has detected 5 Warning Sign with EW. Click here to check it out.
警告！GuruFocus檢測到5個帶有EW的警告信號。按此檢查把它拿出來。
EW 30-Year Financial Data
EW 30年財務數據
The intrinsic value of EW
電子戰的內在價值
Peter Lynch Chart of EW
彼得·林奇的電子戰圖表
Dow tumbles on increased coronavirus fears, suggesting opportunities in health care
陶氏由於對冠狀病毒恐懼的增加，股市暴跌，這表明醫療保健領域存在機會
On Monday, theDow Jones Industrial Averageclosed at 28,533.90, down 455.83 points from Friday's close of 28,989.73, on increased fears over the coronavirus' impact to the global economy. Dow components Nike Inc. (NYSE:NKE) and American Express Co. (NYSE:AXP) contributed to the broad index's decline, which amounted to approximately 540 points at the intraday low.
Severalconsumer cyclicalindustry groups, includingtravel and leisureand restaurants, pulled back as the coronavirus outbreak lowered demand for travel around the globe. On the other hand, health care stocks might see high demand: According to CNBC, China increased medical supplies and staff in Wuhan, the center of the virus outbreak. Further, Wuhan expects to open a 1,000-bed hospital to treat the infected by the end of this week.
隨着冠狀病毒爆發降低了全球旅行需求，包括旅遊、休閒和餐飲業在內的幾個消費週期行業集團紛紛撤退。另一方面，醫療保健類股的需求可能會很高：據CNBC報道，中國增加了武漢的醫療用品和工作人員，武漢是病毒爆發的中心。此外，武漢預計在本週末之前開設一家1000張牀位的醫院來治療感染者。
As such, investors might seek opportunities in health care companies with good financial strength and profitability. The Good Companies screen seeks companies with strong business predictability, high average return on capital and increasing revenue and profit margins over the past 10 years.
因此，投資者可能會在財務實力和盈利能力良好的醫療保健公司尋找機會。Good Companies Screen尋找業務可預測性強、平均資本回報率高、過去10年營收和利潤率不斷提高的公司。
Edwards Lifesciences
愛德華茲生命科學
A Baxter International Inc. (NYSE:BAX) spinoff, Edwards Lifesciences designs, manufactures and markets a range of medical devices and equipment for advanced stages of heart disease. GuruFocus ranks the company's profitability 10 out of 10 on several positive investing signs, which include a high Piotroski F-score of 8, a four-star business predictability rank and operating margins that have increased approximately 6.50% per year over the past five years and are outperforming over 95% of global competitors.
A 巴克斯特國際公司愛德華茲生命科學公司是從愛德華茲生命科學公司(紐約證券交易所市場代碼：BAX)剝離出來的公司，設計、製造和營銷一系列用於心臟病晚期的醫療器械和設備。GuruFocus根據幾個積極的投資跡象將公司的盈利能力評為10分(滿分10分)，其中包括Piotroski F-Score高達8分，四星級業務可預測性排名，以及運營利潤率在過去五年中每年增長約6.50%，表現優於95%以上的全球競爭對手。
Edwards' financial strength ranks 8 out of 10 on the heels of robust interest coverage and a solid Altman Z-score of 15.78.
愛德華茲的財務實力排名第8位(滿分10分)，緊隨其後的是強勁的利息覆蓋和堅實的Altman Z-Score(15.78分)。
Gurus with large holdings in Edwards include Spiros Segalas (Trades, Portfolio) and the Vanguard Health Care Fund (Trades, Portfolio).
持有愛德華茲大量股份的大師包括斯皮羅斯·塞加拉斯(Trades，Portfolio)和先鋒醫療保健基金(Vanguard Health Care Fund，Trades，Portfolio)。
Novo Nordisk
諾和諾德
Novo Nordisk manufactures and markets a variety of human and modern insulins, as well as oral antidiabetic agents. GuruFocus ranks the Denmark-based biotech company's profitability 10 out of 10 on several positive investing signs, which include a five-star business predictability rank, expanding profit margins and a return on equity that outperforms 99% of global competitors.
諾和諾德製造和銷售各種人類和現代胰島素，以及口服降糖藥。GuruFocus根據幾個積極的投資跡象，對這家總部位於丹麥的生物技術公司的盈利能力進行了10分(滿分10分)的排名，這些跡象包括五星級的業務可預測性排名、不斷擴大的利潤率以及表現優於99%的全球競爭對手的股本回報率。
The company's financial strength ranks 8 out of 10 on the heels of strong Altman Z-scores and a debt-to-Ebitda ratio of 0.08, which outperforms approximately 92% of global competitors.
該公司的財務實力排名第8位(滿分10分)，緊隨其後的是Altman Z-Score的強勁表現和0.08的債務與EBITDA比率，表現優於大約92%的全球競爭對手。
Gurus with large holdings in Novo Nordisk include Jim Simons' Renaissance Technologies and Ken Fisher (Trades, Portfolio).
在諾和諾德持有大量股份的大師包括吉姆·西蒙斯(Jim Simons)的文藝復興技術公司(Renaissance Technologies)和肯·費舍爾(Ken Fisher)(交易、投資組合)。
Guangdong Zhongsheng
廣東中生
Guangdong Zhongsheng manufactures and distributes patent medicines and chemical drugs primarily in South China. GuruFocus ranks the company's profitability 9 out of 10 on several positive investing signs, which include a 4.5-star business predictability rank and operating margins that have increased 7.60% per year over the past five years and are outperforming approximately 86.62% of global competitors.
廣東中生主要在華南地區生產和分銷專利藥品和化學藥品。GuruFocus在幾個積極的投資跡象上將公司的盈利能力評為9分(滿分10分)，其中包括4.5星級的業務可預測性排名和營業利潤率，過去5年來，營業利潤率以每年7.60%的速度增長，表現優於大約86.62%的全球競爭對手。
Guangdong Zhongsheng's financial strength ranks 8 out of 10 on the heels of a strong Altman Z-score of 6.48 and debt ratios that outperform over 63% of global competitors.
廣東中盛的財務實力排名第8位(滿分10分)，緊隨其後的是Altman的6.48分和超過63%的全球競爭對手的債務比率。
DongKook Pharmaceutical
東國藥業
DongKook Pharmaceutical produces medicines like Madecassol for wounds and Oramedy for stomatitis. GuruFocus ranks the South Korean drug manufacturer's profitability 9 out of 10 on several positive investing signs, which include a five-star business predictability rank and a return on equity that outperforms over 80% of global competitors.
東國製藥公司生產治療傷口的Madecassol和治療口炎的Oramedy等藥物。GuruFocus在幾個積極的投資跡象上給這家韓國製藥商的盈利能力打了9分(滿分10分)，其中包括五星級的商業可預測性排名和超過80%的全球競爭對手的股本回報率。
The company's financial strength ranks 8 out of 10 on the heels of strong interest coverage and Altman Z-scores. Despite this, debt ratios are outperforming just over 56% of global drug manufacturers.
該公司的財務實力排名第8位(滿分10分)，緊隨其後的是強勁的利息覆蓋和Altman Z-Score。盡管如此，負債率的表現仍好於略高於56%的全球製藥商。
Bumrungrad Hospital
布倫格勒醫院
Bumrungrad Hospital operates diagnostic, therapeutic and intensive care facilities, generating revenues primarily from inpatient and outpatient services in Bangkok. GuruFocus ranks the company's profitability 9 out of 10 on several positive investing signs, which include expanding profit margins, a four-star business predictability rank and a return on assets that outperforms over 93% of global competitors.
Bumrungrad醫院經營診斷、治療和重症監護設施，收入主要來自曼谷的住院和門診服務。GuruFocus在幾個積極的投資跡象上給公司的盈利能力打了9分(滿分10分)，包括不斷擴大的利潤率，四星級的業務可預測性排名，以及超過93%的全球競爭對手的資產回報率。
Disclosure: No positions.
披露：沒有頭寸。
Read more here:
請在這裏閲讀更多內容：
4 US and European Consumer Cyclical Companies With High Business Quality
4家美國和歐洲高商業質量的消費週期公司
5 Chinese Peter Lynch Growth Stocks With High Profitability
5只高盈利的中國彼得·林奇成長型股票
5 European and Asian Net-Nets for the 1st Quarter of 2020
2020年第一季度5個歐洲和亞洲淨網
Not a Premium Member of GuruFocus? Sign up for afree 7-day trial here.
不是GuruFocus的高級會員？在這裏報名參加為期7天的試用期。
This article first appeared onGuruFocus.
這篇文章最早出現在GuruFocus上。
Warning! GuruFocus has detected 5 Warning Sign with EW. Click here to check it out.
警告！GuruFocus檢測到5個帶有EW的警告信號。單擊此處查看。
EW 30-Year Financial Data
EW 30年財務數據
The intrinsic value of EW
電子戰的內在價值
Peter Lynch Chart of EW
彼得·林奇的電子戰圖表
譯文內容由第三人軟體翻譯。